⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TRAW News
Traws Pharma, Inc. Common Stock
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
globenewswire.com
TRAW
Form 8-K
sec.gov
TRAW
Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights
globenewswire.com
TRAW
Traws Pharma Announces Up to $60 Million Private Placement Financing
globenewswire.com
TRAW
Form 8-K
sec.gov
TRAW
Form 8-K
sec.gov
TRAW
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
globenewswire.com
TRAW
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
globenewswire.com
TRAW
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
globenewswire.com
TRAW
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
globenewswire.com
TRAW